Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

BMC Cancer

Table 2 The clinicopathologic characteristics and genetic profiles for patients with ALK rearrangement and c-Met overexpression

Patients		P1	P2	P3	P4	P5	P6	P7	P8	P9	P10	P11	P12	P13	P14	P15
Age (y)		< 60	< 60	< 60	< 60	< 60	< 60	< 60	< 60	< 60	> 60	> 60	< 60	< 60	> 60	< 60
Histology		ADC	ADC	ADC	ADC	ADC	ADC	ADC	ADC	ADC	ADC	ADC	ADC	ADC	ADC	ADC
Stage		IV	IV	IV	IV	IV	IV	IV	IV	IV	IV	IV	IV	IV	IV	IV
Smoking		0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
PS		0	1	1	1	1	1	1	1	1	1	1	0	1	1	1
C-Met	IHC	50%+++, 30%+	70%+++,10%++,20%+	60%+++, 40%++	70%+++,30%+	100%+++	50%+++, 50%++	60%+++, 40%++	60%+++, 40%++	100%+++	50%+++ 50%++	90%+++	90%+++	90%+++	90%+++	90%+++
C-Met	FISH	–	–	–	–	–	ND	–	ND	–	–	ND	ND	ND	ND	ND
ALK	IHC	+	ND	+	ND	ND	ND	+	+	ND	+	+	+	+	+	+
	FISH	ND	60%	ND	29%	20%	74%	ND	ND	60%	ND	ND	ND	ND	ND	ND
	Race-PCR	ND	ND	ND	ND	V3	ND	V1	ND	ND	ND	ND	V1	ND	ND	ND
EGFR		WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	19 del
KRAS		WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT

Abbreviations: F female, M male, ADC adenocarcinoma, PR partial response, m months, ALK anaplastic lymphoma kinase, c-Met cellular-mesenchymal-epithelial transition, EGFR epidermal growth factor receptor, KRAS kirsten rat sarcoma viral oncogene homolog, IHC Ventana immunohistochemistry, FISH fluorescent in situ hybridization, RACE PCR rapid amplification of cDNA ends coupled polymerase chain reaction, ND not done, V variant, 19 del exon 19 deletion

ISSN: 1471-2407